Clinical Trial Update: An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults [Phase 2]

View source ↗

Summary

An exploratory Phase 2 trial evaluated whether a single dose of the Ad26.RSV.preF vaccine could prophylactically prevent Respiratory Syncytial Virus infection i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 2 | Status: COMPLETED | Results posted: 2021-07-23